Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 170

1.

Relationship between hormone receptor status and tumour size, grade and comedo necrosis in ductal carcinoma in situ.

Barnes NL, Boland GP, Davenport A, Knox WF, Bundred NJ.

Br J Surg. 2005 Apr;92(4):429-34.

PMID:
15736216
2.
3.
4.

Oestrogen receptor expression in ductal carcinoma in situ of the breast: relationship to flow cytometric analysis of DNA and expression of the c-erbB-2 oncoprotein.

Poller DN, Snead DR, Roberts EC, Galea M, Bell JA, Gilmour A, Elston CW, Blamey RW, Ellis IO.

Br J Cancer. 1993 Jul;68(1):156-61.

5.

Histological category and expression of hormone receptors in ductal carcinoma in situ of the breast.

Lebrecht A, Buchmann J, Hefler L, Lampe D, Koelbl H.

Anticancer Res. 2002 May-Jun;22(3):1909-11.

PMID:
12168892
6.

The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome in 'pure' ductal carcinoma in situ of the breast.

de Roos MA, van der Vegt B, Peterse JL, Patriarca C, de Vries J, de Bock GH, Wesseling J.

Histopathology. 2007 Aug;51(2):227-38.

PMID:
17650217
7.

Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.

Hussein MR, Abd-Elwahed SR, Abdulwahed AR.

Cell Biol Int. 2008 Jun;32(6):698-707. doi: 10.1016/j.cellbi.2008.01.007. Epub 2008 Jan 25.

PMID:
18296077
8.

Cell biological factors in ductal carcinoma in situ (DCIS) of the breast-relationship to ipsilateral local recurrence and histopathological characteristics.

Ringberg A, Anagnostaki L, Anderson H, Idvall I, Fernö M; South Sweden Breast Cancer Group.

Eur J Cancer. 2001 Aug;37(12):1514-22.

PMID:
11506959
9.

Microinvasive ductal carcinoma (T1mic) of the breast. The clinicopathological profile and immunohistochemical features of 28 cases.

Yang M, Moriya T, Oguma M, De La Cruz C, Endoh M, Ishida T, Hirakawa H, Orita Y, Ohuchi N, Sasano H.

Pathol Int. 2003 Jul;53(7):422-8.

PMID:
12828606
10.

Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.

Pentheroudakis G, Kalogeras KT, Wirtz RM, Grimani I, Zografos G, Gogas H, Stropp U, Pectasides D, Skarlos D, Hennig G, Samantas E, Bafaloukos D, Papakostas P, Kalofonos HP, Pavlidis N, Fountzilas G.

Breast Cancer Res Treat. 2009 Jul;116(1):131-43. doi: 10.1007/s10549-008-0144-9. Epub 2008 Jul 31.

PMID:
18668363
11.

Impact of estrogen receptor expression and other clinicopathologic features on tamoxifen use in ductal carcinoma in situ.

Hird RB, Chang A, Cimmino V, Diehl K, Sabel M, Kleer C, Helvie M, Schott A, Young J, Hayes D, Newman L.

Cancer. 2006 May 15;106(10):2113-8.

12.

Improved outcomes of breast-conserving therapy for patients with ductal carcinoma in situ.

Halasz LM, Sreedhara M, Chen YH, Bellon JR, Punglia RS, Wong JS, Harris JR, Brock JE.

Int J Radiat Oncol Biol Phys. 2012 Mar 15;82(4):e581-6. doi: 10.1016/j.ijrobp.2011.08.015. Epub 2011 Dec 28.

PMID:
22208975
13.

Differences in the pathologic and molecular features of intraductal breast carcinoma between younger and older women.

Rodrigues NA, Dillon D, Carter D, Parisot N, Haffty BG.

Cancer. 2003 Mar 15;97(6):1393-403.

14.

Immunohistochemical detection of oestrogen receptors in ductal carcinoma in situ of the breast.

Karayiannakis AJ, Bastounis EA, Chatzigianni EB, Makri GG, Alexiou D, Karamanakos P.

Eur J Surg Oncol. 1996 Dec;22(6):578-82.

PMID:
9005143
15.

Estrogen receptor alpha and beta, progesterone receptor, pS2 and HER-2/neu expression delineate different subgroups in ductal carcinoma in situ of the breast.

Rody A, Diallo R, Poremba C, Speich R, Wuelfing P, Kissler S, Solbach C, Kiesel L, Jackisch C.

Oncol Rep. 2004 Oct;12(4):695-9.

PMID:
15375487
16.

[ErbB-2 expression and hormone receptor status in areas of transition from in situ to invasive ductal breast carcinoma].

Peres RM, Derchain SF, Heinrich JK, Serra KP, Pinto GA, Soares FA, Sarian LO.

Rev Bras Ginecol Obstet. 2009 Sep;31(9):461-7. Portuguese.

17.

Expression of androgen receptor and two androgen-induced proteins (apolipoprotein D and pepsinogen C) in ductal carcinoma in situ of the breast.

Gonzalez LO, Corte MD, Junquera S, Bongera M, Rodriguez JC, Vizoso FJ.

Histopathology. 2007 Jun;50(7):866-74.

PMID:
17543076
18.

Ductal carcinoma in situ of the breast in Singapore: recent trends and clinical implications.

Tan KB, Lee HY, Putti TC.

ANZ J Surg. 2002 Nov;72(11):793-7.

PMID:
12437689
20.

A multifactorial analysis of steroid hormone receptors in stages I and II breast cancer.

Kohail HM, Elias EG, el-Nowiem SA, Bashirelahi N, Didolkar MS, Reed WP.

Ann Surg. 1985 May;201(5):611-7.

Supplemental Content

Support Center